DDInter708 DDInter1376
Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients with refractory epilepsy. FDA approved in June 10, 2011 under the name of ezogabine.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Ezogabine {u} (Compound) resembles {v} (Compound) Flupirtine
Ezogabine {u} (Compound) binds {v} (Gene) UGT1A1
Ezogabine {u} (Compound) is included by {v} (Pharmacologic Class) Potassium Channel Openers
Ezogabine {u} (Compound) causes {v} (Side Effect) Ill-defined disorder
Ezogabine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Ezogabine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Ezogabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Palonosetron
Ezogabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Ezogabine {u} may lead to a major life threatening interaction when taken with {v} Nilotinib
Ezogabine {u} may lead to a major life threatening interaction when taken with {v} Crizotinib
Ezogabine (Compound) resembles Flupirtine (Compound)
Ezogabine (Compound) binds UGT1A1 (Gene)
Ezogabine (Compound) is included by Potassium Channel Openers (Pharmacologic Class)
Ezogabine (Compound) causes Ill-defined disorder (Side Effect)
Ezogabine may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Ezogabine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Ezogabine may cause a moderate interaction that could exacerbate diseases when taken with Palonosetron
Ezogabine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Ezogabine may lead to a major life threatening interaction when taken with Nilotinib
Ezogabine may lead to a major life threatening interaction when taken with Crizotinib